World-class Immuno-Oncology experts to understand cancer immunotherapeutic response, NEX-I is aligned to find the right solution and suggests a new standard for immunotherapy.
2025
07
Secured Series B Investment ($43M)
05
Received the Minister of Trade, Industry and Energy Award at the 60th Invention Day ceremony
03
Expansion of Corporate Research Institute
02
Technology Export Award (NXI-101) at the 26th Korea Drug Development Awards
Excellent Specialist Award for Pharmaceutical Industry Innovation and Commercialization Linkage (Commendation from the President of the KHIDI)
2024
12
KDDF’s award for ‘2024 High Performance’ in excellence of project
PMDA Approval for NXI-101 Phase 1 Clinical Trial
11
Research collaboration agreement with GC Biopharma to generate novel drug candidates for immunotherapy-resistant cancers
Minister’s award for ‘2024 DIPS GLOBAL TECH CON’ by the Ministry of SMEs and Startups
Minister’s award for ‘2024 Korea Biotechnology Industry Day’ by the Ministry of South Korean Ministry of Trade, Industry and Energy
04
NXI-101 AACR 2024 Presentation
03
NXI-101 License Out to Ono Pharmaceutical Co., Ltd.
02
NXI-101 Patent Registration
2023
11
Bio Europe Presentation
10
MOU signed - NSCLC PoC validation study with Xsphera
05
[ONCOKINE® Discovery Platform] Published Nature Communications (IF=17.6) Overcoming the resistance of cisplatin treatment through autophagy inhibition
04
Awarded for government initiative program, “All-stage Pharmaceutical industry global expansion” by KHIDI
Awarded for government initiative program, “Unconquerable Startups 1000+ Project” by the Ministry of SMEs and Startups
03
MOU signed - Joint research agreement for AI-driven development of new antibody with Arontier Co., Ltd.
2022
12
Showcasing cutting-edge research on resistance mechanisms in a poster presentation at the ESMO I-O Congress
11
Professor Apotolia Maria Tsimberidou, a world-renowned clinical expert in oncology from MD Anderson, joined our distinguished Scientific Advisory Board (SAB)
10
Series-A Funding 22 billion KRW
05
Publication of ONCOKINE™ Discovery Platform, New anticancer immunotherapy strategy technology: Journal of controlled release, (IF=11.467)
[Validation on Technology for Identifying Immunotherapy Refractory Factor] Published Nature Communications (IF=17.694) Identification of causal factors in resistance against anti-PD-L1 treatment
04
Execution of GLP Tox. non-clinical research CRO agreement
03
Renovation of R&D Center
Center for Laboratory Animal Research Approved by MFDS (located at the R&D center)
Publication of ONCOKINE™ Discovery Platform, Immunotherapy refractory mechanism study: The Journal of Clinical Investigation (IF=19.456)
01
Started Government grants by Asan Medical Center Bio Core Facility
2021
12
Execution of MOU – Daewoong for R&D collaboration of cancer immunotherapy and long-term business strategy
Pre-A Funding 5 billion KRW
11
Awarded government grants for NXI-101 research and development by KDDF
Execution of CDMO agreement
10
Awarded government grants by TIPS (Tech Incubator Program for Startup)
09
Certification of Venture Business
06
Awarded government grants for NXI-201 research and development by KDDF